XML 19 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements Of Cash Flows (USD $)
In Thousands, unless otherwise specified
 12 Months Ended 120 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2011
Cash flows used in operating activities:      
Net loss $ (5,364) $ (8,420) $ (63,674)
Adjustments to reconcile net loss to net cash used in operating activities:      
Gain on patent rights assignment (2,000)   (2,000)
Gain on bargain purchase     (25,282)
Depreciation and amortization 602 338 1,737
Non-cash interest expense     211
Share-based compensation 308 458 2,282
Issuance of warrants for lease termination     377
Accretion of liabilities     152
Impairment of property and equipment     125
Impairment of in-process research and development     6,000
Write-off of deferred tax liability     (2,281)
Gain on marketable securities available for sale   (263) (263)
(Gain) loss from disposal of property and equipment 16 (4) 83
Other, net     267
Change in operating assets and liabilities (net of amounts acquired):      
Other current assets 14 58 2,542
Other assets 80 84 7,246
Accounts payable (128) (145) (1,930)
Accrued expenses and other liabilities (220) (316) (18,984)
Deferred rent (267) (114) 49
Net cash used in operating activities (6,959) (8,324) (93,343)
Cash flows provided by investing activities:      
Cash received from Merger     30,392
Payment of deferred transaction costs     (1,186)
Purchase of property and equipment (19) (4) (1,879)
Proceeds from sale of marketable securities   263 15,369
Proceeds from sale of property and equipment 25 6 358
Proceeds from patent rights assignment 2,000    2,000
Net cash provided by investing activities 2,006 265 45,054
Cash flows provided by (used in) financing activities:      
Proceeds from issuance of convertible notes payable and related warrants for common stock     10,841
Proceeds from issuance of bank note payable     4,000
Proceeds from stock subject to repurchase     38
Proceeds from the issuance of preferred stock     32,316
Proceeds from the issuance of common stock 4,726 7,659 12,581
Repayment of principal on bank note payable     (4,000)
Repayment of principal on convertible notes payables     (105)
Repayment of principal on vendor finance agreement (146)    (146)
Net cash provided by (used in) financing activities 3,871 7,321 54,232
Net (decrease) increase in cash and cash equivalents (1,082) (738) 5,943
Cash and cash equivalents, beginning of period 7,025 7,763  
Cash and cash equivalents, end of period 5,943 7,025 5,943
Supplemental cash flow information:      
Interest paid 5   112
Supplemental disclosure of noncash investing and financing transactions:      
Accrued interest on notes payable converted to equity     163
Warrant issued in connection with credit facility     111
Accrued deferred transaction costs     482
Common Stock [Member]
      
Cash flows provided by (used in) financing activities:      
Payment of offering costs (709) (338) (1,047)
Preferred Stock [Member]
      
Cash flows provided by (used in) financing activities:      
Payment of offering costs     $ 246